Back to Search Start Over

Household Transmission and Clinical Features of SARS-CoV-2 Infections.

Authors :
McLean HQ
Grijalva CG
Hanson KE
Zhu Y
Deyoe JE
Meece JK
Halasa NB
Chappell JD
Mellis AM
Reed C
Belongia EA
Talbot HK
Rolfes MA
Source :
Pediatrics [Pediatrics] 2022 Mar 01; Vol. 149 (3).
Publication Year :
2022

Abstract

Objectives: Examine age differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission risk from primary cases and infection risk among household contacts and symptoms among those with SARS-CoV-2 infection.<br />Methods: People with SARS-CoV-2 infection in Nashville, Tennessee and central and western Wisconsin and their household contacts were followed daily for 14 days to ascertain symptoms and secondary transmission events. Households were enrolled between April 2020 and April 2021. Secondary infection risks (SIR) by age of the primary case and contacts were estimated using generalized estimating equations.<br />Results: The 226 primary cases were followed by 198 (49%) secondary SARS-CoV-2 infections among 404 household contacts. Age group-specific SIR among contacts ranged from 36% to 53%, with no differences by age. SIR was lower in primary cases age 12 to 17 years than from primary cases 18 to 49 years (risk ratio [RR] 0.42; 95% confidence interval [CI] 0.19-0.91). SIR was 55% and 45%, respectively, among primary case-contact pairs in the same versus different age group (RR 1.47; 95% CI 0.98-2.22). SIR was highest among primary case-contact pairs age ≥65 years (76%) and 5 to 11 years (69%). Among secondary SARS-CoV-2 infections, 19% were asymptomatic; there was no difference in the frequency of asymptomatic infections by age group.<br />Conclusions: Both children and adults can transmit and are susceptible to SARS-CoV-2 infection. SIR did not vary by age, but further research is needed to understand age-related differences in probability of transmission from primary cases by age.<br />Competing Interests: CONFLICT OF INTEREST DISCLOSURES: Dr Halasa reports grants from Sanofi and Quidel. Dr Grijalva reports grants from Campbell Alliance/Syneos, the National Institutes of Health, the Food and Drug Administration, the Agency for Health Care Research and Quality and Sanofi-Pasteur, and consultation fees from Pfizer, Merck, and Sanofi-Pasteur. Other authors have no conflicts of interest relevant to this article to disclose.<br /> (Copyright © 2022 by the American Academy of Pediatrics.)

Details

Language :
English
ISSN :
1098-4275
Volume :
149
Issue :
3
Database :
MEDLINE
Journal :
Pediatrics
Publication Type :
Academic Journal
Accession number :
35194642
Full Text :
https://doi.org/10.1542/peds.2021-054178